Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
Fiche publication
Date publication
mars 2024
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain
Tous les auteurs :
Boidot R, Blum MGB, Wissler MP, Gottin C, Ruzicka J, Chevrier S, Delhomme TM, Audoux J, Jeanniard A, Just PA, Harter P, Pignata S, González-Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Duforet-Frebourg N, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E,
Lien Pubmed
Résumé
The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies on shallow Whole Genome Sequencing (sWGS) to capture genomic instability and targeted sequencing to determine BRCA status.
Mots clés
BRCA, Genomic instability, Homologous recombination deficiency, Low-pass sequencing, Ovarian cancer, PARP-inhibitor, Whole genome sequencing
Référence
Eur J Cancer. 2024 03 2;202:113978